Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Keith Kaye

General ID · RU

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Erin Bonura

General ID · OHSU

View

Dr. Nizar Wehbi

General ID

View

Dr. Robert Schooley

General ID · UCSD

View

Dr. Priya Nori

General ID · MMC

View

Dr. Jan Patterson

General ID · UTHSCSA

View

Dr. Kavita Bhavan

General ID · Dallas County Hospital District

View

Dr. John Goldman

General ID · UPMC Central PA

View

Dr. Gonzalo Bearman

General ID · Medical College of Virginia

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023-2024 Season, United States.

    Oct 6, 2025DOI: 10.1093/cid/ciae597Journal ArticleCID

    Written by: Mark W TenfordeEmily L ReevesZachary A WeberSara Y TartofNicola P KleinKristin DascombMalini B DeSilvaDuck-Hye YangShaun J GrannisStephanie A IrvingToan C OngRuth Link-GellesS Bianca SalasLina S SyBruno LewinRichard ContrerasOusseny ZerboBruce FiremanJohn HansenJulius TimbolTamara SheffieldDaniel BrideJulie ArndorferJosh VanOtterlooCharlene E McEvoyOmobosola O AkinseteInih J EssienBrian E DixonColin RogersonWilliam F FadelThomas DuszynskiAllison L NalewayMichelle A BarronSuchitra RaoDavid MayerCatia ChavezSarah W BallAmanda B PayneCaitlin RayMonica DickersonVarsha NeelamKatherine AdamsBrendan FlanneryJennifer DeCuirShikha Garg

    Find these authors on Roon

    SG
    Dr. Shikha Garg
    General ID · VAMC

    INTRODUCTION

    During the 2023–2024 influenza season, the United States experienced at least 380,000 influenza-associated hospitalizations and 17,000 deaths [1]. The highest incidence of influenza-associated hospitalizations was observed among adults aged ≥65 years, followed by adults aged 50–64 years and children aged 0–4 years [2]. A mix of influenza virus types and sub-types circulated [3]. Through May 4, 2024, data from U.S. clinical and public health laboratories found that 71% of tested viruses were influenza A viruses (69% subtyped as H1N1pdm09 and 31% as H3N2) and 29% were influenza B/Victoria viruses. Antigenic characterization suggested that reference strains used in the 2023–2024 Northern Hemisphere vaccine were well matched to circulating influenza viruses [3].Seasonal influenza vaccination is recommended in the United States for all people aged ≥6 months annually [4]. However, the United States has experienced a broad decline in vaccine uptake during recent seasons. In December 2023, the Centers for Disease Control and Prevention issued a health alert highlighting increased risk of influenza-associated illness due to low immunization rates [5]. The burden of influenza illness can be reduced substantially with increased vaccine uptake, even in seasons with low or moderate influenza vaccine effectiveness (VE) [6–8].From a multi-site VE network, we evaluated the effectiveness of the 2023–2024 influenza vaccine in preventing influenza-associated hospitalizations and emergency department (ED) or urgent care (UC) encounters among children, adolescents, and adults.

    METHODS

    VIrtual SARS-CoV-2, Influenza, and Other respiratory viruses Network (VISION) is an electronic health record-based network that performs real-world evaluations of VE for respiratory viruses. This study included acute respiratory illness (ARI)-associated medical encounters among individuals aged ≥6 months. Seven sites in 8 states contributed encounter data (Kaiser Permanente Northern California, Kaiser Permanente Southern California, UCHealth in Colorado, Regenstrief Institute in Indiana, HealthPartners in Minnesota and Wisconsin, Kaiser Permanente Northwest in Oregon and Washington, and Intermountain Healthcare in Utah). The study sampled ARI-associated encounters between October 15, 2023 and April 30, 2024.As previously described [9], we used a test-negative design to evaluate influenza VE by comparing the odds of influenza vaccination in influenza-positive cases versus influenza-negative controls. We included children and adolescents (aged 6 months-17 years) and adults (aged ≥18 years) with ARI-associated ED/UC encounters or hospitalizations of ≥24 hours duration. ARI was defined by (ICD-10) codes for acute respiratory clinical diagnoses or acute respiratory signs or symptoms at the encounter (Supplementary Table 1). All patients received molecular testing for influenza as well as SARS-CoV-2 within 10 days before or up to 72 hours after the ED/UC visit or admission date. An individual could contribute more than one encounter; multiple ED and/or UC encounters within a 7-day period were combined into a single ED/UC encounter and hospitalizations within 30 days combined into a single hospitalization.
    International Classification of Diseases, Tenth Revision
    Baseline patient demographic and clinical information, including underlying medical conditions (Supplementary Table 2), was extracted from electronic health records (EHRs), along with in-hospital outcomes. Influenza vaccination status was ascertained from EHRs, state immunization information systems, and/or claims data. When available, information on vaccine type was collected. A patient was classified as vaccinated if they received ≥1 dose of a 2023–2024 influenza vaccine on or after August 1, 2023 and ≥14 days prior to the encounter index date (the earliest date of the most recent influenza test or the date of the ED/UC visit or hospital admission). A patient was considered unvaccinated if 2023–2024 influenza vaccination was not documented before the encounter index date. Certain children aged 6 months-8 years required 2 doses of influenza vaccine for the season based on their vaccination history [4]; partial versus full vaccination was not assigned for these children due to incomplete capture of vaccination history for past seasons.
    Exclusion criteria are shown in Supplementary Figure 1A and 1B. Encounters with no influenza molecular test result, a diagnosis of influenza without a confirmatory positive laboratory test, or that occurred 1–13 days after influenza vaccination were excluded. We also excluded encounters with a SARS-CoV-2 positive test or COVID-19 ICD-10 discharge diagnostic code to reduce potential bias in influenza VE estimates due to correlation between influenza and COVID-19 vaccination [10].
    Baseline patient characteristics were described using counts and percentages or medians and interquartile ranges. Standardized mean differences (SMDs) were calculated to compare patient characteristics by influenza vaccination status and case/control status. An SMD >0.20 was interpreted as a meaningful difference in distribution between groups. VE against influenza-associated hospitalizations and ED/UC encounters was estimated from logistic regression models comparing the odds of influenza vaccination between cases and controls, adjusting for pre-specified potential confounders used in prior VISION analyses: site, calendar day, patient age (in years), sex, and race/ethnicity reported in the EHR [11, 12]. VE was calculated as (1 – adjusted odds ratio) × 100. Calendar day and age were modeled as natural cubic splines with 4 degrees of freedom.
    We estimated VE separately for children and adolescents and for adults by encounter setting (ED/UC encounters or hospitalizations). Results were further stratified by age group (6 months-4 years, 5–17 years, 18–49 years, 50–64 years, ≥65 years), by influenza virus type (A or B), by time since vaccination in a model with 4 exposure groups (unvaccinated and 14–59 days, 60–119 days, ≥120 days since vaccination), and by presence or absence of ≥1 likely immunocompromising conditions. Intervals for waning models were selected based on distribution of time since vaccination and seasonal influenza circulation patterns for most influenza seasons where most infections occur over several months in the fall and winter. Among ARI-associated hospitalizations, we evaluated VE against critical in-hospital outcomes, defined as intensive care unit (ICU) admission and/or death. For this analysis, cases included patients hospitalized with influenza who experienced a critical outcome, and controls were all hospitalized controls [13]. We also estimated VE against ED and UC encounters separately. Finally, because of differences by care setting in the proportion of influenza A and B cases and timing of vaccination across age groups, we stratified type-specific VE by age group and time since vaccination.
    SAS version 9.4 (SAS Institute, Inc.) or R version 4.1.0 (R Foundation for Statistical Computing) were used to conduct analyses. These activities were reviewed and approved by institutional review boards (IRBs) at Kaiser Permanente Northern California and Kaiser Permanente Southern California (45 C.F.R. part 46.101(c); 21 C.F.R. part 56). The Westat IRB determined that the activities are non-research. Patient informed consent was not required.

    RESULTS

    A total of 79,374 ARI-associated hospitalizations and 308,389 ARI-associated ED/UC encounters were identified; 9,067 (11.4%) hospitalizations and 37,090 (12.0%) ED/UC encounters met ≥1 exclusion criterion (Supplementary Figure 1A and 1B). After exclusions, 70,307 (88.6%) hospitalizations and 271,299 (88.0%) ED/UC encounters were included in analyses. Among 70,307 hospitalizations, 3,500 individuals had >1 hospitalization during the study period. Among 271,299 ED/UC encounters, 15,707 individuals had >1 ED/UC encounter.
    Influenza activity peaked in late December to early January (Supplementary Figures 2A–2D). Of influenza cases, 48,757 (75.7%) were influenza-A-positive, 15,862 (24.6%) were influenza-B-positive, with 172 (0.3%) mixed A and B infections. The proportion of influenza B cases was higher in children and adolescents (34.4% of cases) than in adults (20.9% of cases).
    Of 3,479 ARI-associated hospitalizations in children and adolescents, 340 (9.8%) were influenza cases and 3,139 (90.2%) were test-negative controls; influenza positivity was 5.3% among children aged 6 months-4 years and 16.6% among those aged 5–17 years. Proportions of hospitalizations among patients with ≥1 documented underlying medical condition were similar for influenza cases (63.8%) and controls (65.1%) [Table 1]. Overall, 1,270 (36.5%) hospitalized patients had received influenza vaccination (18.5% of cases vs 38.5% of controls, SMD = 0.45). Among vaccinated patients, median time since vaccination was 96 days; 91 days for those aged 6 months-4 years and 110 days for those aged 5–17 years.
    Among 70,521 ARI-associated ED/UC encounters in children and adolescents, 17,493 (24.8%) were cases and 53,028 (75.2%) were controls; influenza positivity was 14.8% among children aged 6 months-4 years and 32.9% among those aged 517 years (Table 1). Overall, 19,728 (28.0%) had received influenza vaccination prior to the encounter. Children aged 6 months-4 years were more likely to be vaccinated than those aged 517 years (34.3% vs 22.9%, SMD = 0.28). Cases were less likely to be vaccinated than controls (15.4% vs 32.1%, SMD = 0.40). Among vaccinated patients, median time since vaccination was 91 days; 86 days for those aged 6 months-4 years and 98 days for those aged 5–17 years.
    Across care settings, 90.0% of vaccinated children with known vaccine product received standard-dose, egg-based inactivated vaccine, 6.8% received cell-culture-based vaccine, 2.9% live-attenuated influenza vaccine, and 0.2% another product type (Supplementary Table 3).
    VE against pediatric influenza-associated hospitalization was 58% (95% confidence interval 71% (95% CI: 51–83%) for children aged 6 months-4 years and 49% (95% CI: 27–65%) for those aged 5–17 years (Figure 1). VE against influenza B viruses (85% [95% CI: 72–93%]) was higher than against influenza A viruses (44% [95% CI: 23–60%]). VE against ICU admission was 43% (95% CI: −6–70%).
    Estimates of VE against influenza-associated ED/UC encounters were consistent with VE against hospitalization and ICU admission. Overall VE against ED/UC encounters was 58% (95% CI: 56–60%); 65% (95% CI: 62–68%) for children aged 6 months-4 years and 54% (95% CI: 51–57%) for children aged 5–17 years (Figure 1). VE against influenza B-associated ED/UC encounters (74% [95% CI: 72–77%]) was higher than against influenza A-associated illness (49% [95% CI: 46–51%]). VE in ED and UC settings was similar (59% and 58%, respectively).
    Of 66,828 ARI-associated hospitalizations in adults, 5,721 (8.6%) were influenza cases and 61,107 (91.4%) were controls; influenza positivity was 11.3% among adults aged 18–64 years and 7.2% among adults aged ≥65 years (Table 2). Median age was 67 years for cases and 72 years for controls, and most patients had ≥1 documented underlying medical condition (86.4% of cases and 92.0% of controls). Among hospitalized adults, 32,455 (48.6%) were vaccinated, including 35.1% of cases versus 49.8% of controls (SMD = 0.30). Of those vaccinated, median time since vaccination was 107 days; 103 days for those aged 18–49 years, 103 days for those aged 50–64 years, and 109 days for those aged ≥65 years. Of hospitalized cases, 824 (14.4%) were admitted to an ICU and 190 (3.3%) died during hospitalization.
    Among 200,778 ARI-associated ED/UC encounters in adults, 40,893 (20.4%) were influenza cases and 159,885 (79.6%) were controls; influenza positivity was 24.5% among adults aged 18–64 years and 11.4% among adults aged ≥65 years. Cases were younger on average than controls (median age 42 vs 54 years) and less likely to have ≥1 documented underlying medical condition (20.5% of cases vs 36.1% of controls, SMD = 0.35; Table 2). Overall, 76,988 (38.3%) were vaccinated (23.5% of cases vs 42.1% of controls, SMD = 0.40). Among vaccinated adults, median time since vaccination was 103 days; 98 days for those aged 18–49 years, 101 days for those aged 50–64 years, and 106 days for those aged ≥65 years.
    Across sites, most (85.5%) vaccinated adults aged 18–64 years with known vaccine type received standard-dose, egg-based inactivated vaccine (Supplementary Table 3). Most (90.3%) older adults received a high-dose inactivated or adjuvanted vaccine, which are preferentially recommended products for older adults [14].
    VE against influenza-associated hospitalization in adults was 39% (95% CI: 35–43%); 51% (95% CI: 42–60%) for adults aged 18–49 years, 40% (95% CI: 32–48%) for adults aged 50–64 years, and 36% (95% CI: 31–41%) for adults aged ≥65 years (Figure 2). VE against influenza B viruses (67% [95% CI: 54–76%]) was higher than against influenza A viruses (37% [95% CI: 32–41%]). VE against critical illness (ICU admission and/or death) was 41% (95% CI: 30–49%); 41% (95% CI: 31–50%) against ICU admission and 50% (95% CI: 31–65%) against in-hospital death.
    As observed for pediatric patients, VE against ED/UC encounters was similar to VE against hospitalization and ICU admission among adult age groups. VE against influenza-associated ED/UC encounters was 47% (95% CI: 46–49%); 54% (95% CI: 53–56%) for ages 18–49 years, 44% (95% CI: 40–47%) for ages 50–64 years, and 37% (95% CI: 34–40%) for adults aged ≥65 years (Figure 2). VE against influenza -associated ED/UC encounters among adults was 75% (95% CI: 72–77%) for influenza B versus 41% (95% CI: 39–42%) for influenza A.
    In analyses of time since vaccination, vaccination provided significant protection against hospitalizations and ED/UC visits through ≥120 days after vaccination (Figure 1–3, Supplementary Table 4). Among children, we observed no significant differences in VE against hospitalization at 14–59 days (50% [95% CI: 18–71%]) versus ≥120 days versus (67% [95% CI: 45–81%]) after vaccination (Figure 1). VE against ED/UC encounters was 63% (95% CI: 60–66%) at 14–59 days versus 56% (95% CI: 53–59%) at 60–119 and 57% (95% CI: 53–60%) ≥120 days after vaccination. Type-specific VE estimates stratified by age group and time since vaccination are shown in Figure 3B and Supplementary Table 4. For children and adolescents, VE against influenza A-associated encounters trended downward with greater time since vaccination, with most difference observed for encounters ≥60 days since vaccination, although no consistent trend was observed against influenza B-associated encounters.
    Among hospitalized adults, VE at 14–59 days after vaccination (49% [95% CI: 42–55%]) was higher than at 60–119 and ≥120 days after vaccination (Figure 2). Against influenza-associated ED/UC encounters, VE was lower with increased time since vaccination (e.g., 57% [95% CI: 55–60%] at 14–59 days vs 48% [95% CI: 45–50%] at ≥120 days since vaccination). Within strata of time since vaccination, VE against influenza A- and B-associated encounters tended to be lower in older compared to younger adults (Figure 3, Supplementary Table 4).

    DISCUSSION

    During the 2023–2024 U.S. influenza season, influenza vaccination reduced the risk of influenza-associated encounters across age groups and care settings, including against severe in-hospital outcomes. These findings support current recommendations for routine annual influenza vaccination beginning at 6 months of age [4].
    Greatest vaccine protection was observed in children aged 6 months-4 years, which is notable given the elevated risk of severe influenza-associated outcomes among young children, including those with no underlying medical conditions [15]. VE among children and adolescents was generally higher than among adults, with more sustained protection. Overall and type-specific VE estimates were lowest among older adults. This could be due to a number of factors, such as primary reasons or thresholds for admission that may be age-related (e.g., due to exacerbation of chronic underlying medical condition after influenza virus infection versus primary viral lower respiratory tract disease), age-related changes including immunosenescence in older adults [16], or effects of repeat vaccination over multiple seasons on immune responses [17, 18]. Protection among older adults was less than for adults aged 18–64 despite preferential receipt of high-dose and adjuvanted influenza vaccines for older adults [4].
    VE was consistently higher against influenza B vs influenza A-associated encounters. Following the emergence of influenza A(H1N1)pdm09 viruses in 2009, population immunity to A(H1N1)pdm09 viruses in younger age groups increased over several seasons. During that period, VE against A(H1N1)pdm09 was similar to VE against B/Yamagata and B/Victoria-associated outpatient illness, while VE against A(H3N2) has been lower, especially among older adults [19]. B/Yamagata viruses no longer circulate and influenza B/Victoria viruses have remained antigenically similar since the emergence of the V1.3 clade but had not circulated for 3 seasons. Lower baseline antibody levels in the population without boosting from natural infection may have resulted in relatively higher levels of protective antibody among vaccinated persons this season. In contrast, levels of protective antibodies against circulating A(H1N1)pdm09 viruses may have been more similar among vaccinated and unvaccinated individuals. Improved understanding of virus and antigen-specific vaccine responses may inform development of more effective influenza vaccines.
    Protection was observed for more than 120 days after vaccination. Among adults, VE estimates were highest 14–59 days post-vaccination. The timing of influenza activity varies from season to season, and optimal timing for vaccination is difficult to predict [20]. CDC’s Advisory Committee on Immunization Practices recommends that most people who require 1 vaccine dose in a season are offered vaccination in September or October, balancing factors including unpredictability of influenza activity, within-season waning of VE [21, 22], and programmatic considerations [4]. In addition to vaccination, other tools may reduce the risk of complications from influenza among older adults and others at increased risk for severe outcomes, such as timely influenza antiviral treatment [23].
    This analysis was subject to several limitations. VE estimates were limited to influenza A- and B-associated encounters because VISION relies on clinician-driven testing and influenza A viruses were not consistently subtyped. During the 2023–2024 influenza season, influenza A(H1N1)pdm09 viruses co-circulated with A(H3N2) and B/Victoria viruses. Influenza A(H3N2) VE has historically been lower than for A(H1N1)pdm09 [19, 24, 25] and co-circulation likely influenced VE against influenza A-associated hospitalizations and ED/UC encounters. As influenza A(H3N2) activity peaked later than A(H1N1)pdm09 activity, declines in VE by time since vaccination may reflect both waning in vaccine-induced immune protection [26] and changes in the distribution of influenza A virus subtypes circulating. Second, we did not have information on influenza vaccination across multiple seasons to evaluate effects from current- and prior-season vaccination [17, 18] or VE in younger children based on partial versus full vaccination [4]. Third, we did not evaluate influenza VE by vaccine type which may impact immune responses and effectiveness [26–28]. Most younger adults received egg-based standard-dose inactivated vaccines whereas most older adults received high-dose inactivated or adjuvanted vaccines. Fourth, the study population may not be representative of the entire U.S. population. Fifth, although vaccination data was captured from a variety of data sources, under-capture of vaccine doses administered in cases or controls could result in vaccination exposure misclassification and potential bias in VE estimates.

    Conclusions

    Influenza vaccination provided protection against influenza-associated encounters for U.S. children, adolescents, and adults during the 2023–2024 influenza season including against severe in-hospital outcomes. Increased uptake of annual influenza vaccination should be strongly encouraged to decrease the burden of influenza illness and its sequelae.
    SG

    Dr. Shikha Garg

    Infectious Disease · General Infectious Disease
    Atlanta VA Medical Center
    shikhag